ImmuPharma plc (LON:IMM – Get Free Report) was up 168.7% during mid-day trading on Thursday . The stock traded as high as GBX 3.80 ($0.05) and last traded at GBX 3.22 ($0.04). Approximately 61,345,711 shares were traded during trading, an increase of 451% from the average daily volume of 11,133,673 shares. The stock had previously closed at GBX 1.20 ($0.01).
ImmuPharma Stock Performance
The company has a market cap of £13.43 million, a price-to-earnings ratio of -322.40 and a beta of 1.53. The company has a 50-day simple moving average of GBX 1.36 and a 200-day simple moving average of GBX 1.63.
About ImmuPharma
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease.
Featured Stories
- Five stocks we like better than ImmuPharma
- Using the MarketBeat Dividend Tax Calculator
- 3 Smart Picks: Discounted Stocks for Savvy Investors
- How to Invest in the Best Canadian Stocks
- NVIDIA Deal Ignites Aurora Stock’s Explosive Potential
- How to buy stock: A step-by-step guide for beginners
- Why AMD Stock Might Already Be This Year’s Best Buy
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
